Chemistry:Lopinavir

From HandWiki
Short description: Chemical compound
Lopinavir
Lopinavir structure.svg
Lopinavir-PDBe-ligand-AB1-from-PDB-xtal-1MUI-Mercury-3D-balls.png
Clinical data
Other namesABT-378
AHFS/Drugs.comInternational Drug Names
MedlinePlusa602015
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityUnknown
Protein binding98-99%
MetabolismLiver
Elimination half-life5 to 6 hours
ExcretionMostly fecal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC37H48N4O5
Molar mass628.814 g·mol−1
3D model (JSmol)
  (verify)

Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir (lopinavir/ritonavir).[1]

It was patented in 1995 and approved for medical use in 2000.[2]

Side effects

Side effects, interactions, and contraindications have only been evaluated in the drug combination lopinavir/ritonavir.[citation needed]

Pharmacology

Lopinavir is highly bound to plasma proteins (98–99%).[3]

Reports are contradictory regarding lopinavir penetration into the cerebrospinal fluid (CSF). Anecdotal reports state that lopinavir cannot be detected in the CSF; however, a study of paired CSF-plasma samples from 26 patients receiving lopinavir/ritonavir found lopinavir CSF levels above the IC50 in 77% of samples.[4]

Research

A 2014 study indicates that lopinavir is effective against the human papilloma virus (HPV). The study used the equivalent of one tablet twice a day applied topically to the cervices of women with high-grade and low-grade precancerous conditions. After three months of treatment, 82.6% of the women who had high-grade disease had normal cervical conditions, confirmed by smears and biopsies.[5] Lopinavir has been shown to impair protein synthesis via AMP-activated protein kinase (AMPK) and eEF2 kinase (eEF2K) activation, a mechanism that is similar to the antiviral effect of protein phosphatase 1 inhibitors.[6][7]

Lopinavir was found to inhibit MERS-CoV replication in the low-micromolar range in cell cultures.[8] In 2020, lopinavir/ritonavir was found not to work in severe COVID-19. In this trial the medication was started typically around 13 days after the start of symptoms.[9]

References

  1. "FDA Approved Drug Products: Kaletra". http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=KALETRA&CFID=26857748&CFTOKEN=5e0033c7f3434629-F5F0F717-D23E-F790-EB3406425F2FD57C. 
  2. Analogue-based Drug Discovery. John Wiley & Sons. 2006. p. 510. ISBN 9783527607495. https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA510. 
  3. Kaletra (lopinavir/ritonavir) capsules; (lopinavir/ritonavir) oral solution. Prescribing information. April 2009
  4. "Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV". AIDS 19 (9): 949–52. June 2005. doi:10.1097/01.aids.0000171409.38490.48. PMID 15905676. 
  5. HIV drug used to reverse effects of virus that causes cervical cancer University of Manchester, 17 February 2014.
  6. "Protein phosphatase 1 regulates Human Cytomegalovirus protein translation by restraining AMPK signaling". Frontiers in Microbiology 12: 698603. 2021. doi:10.3389/fmicb.2021.698603. ISSN 1664-302X. PMID 34335531. 
  7. "1E7-03, a low MW compound targeting host protein phosphatase-1, inhibits HIV-1 transcription". British Journal of Pharmacology 171 (22): 5059–75. November 2014. doi:10.1111/bph.12863. PMID 25073485. 
  8. "Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture". Antimicrobial Agents and Chemotherapy 58 (8): 4875–84. August 2014. doi:10.1128/AAC.03011-14. PMID 24841269. 
  9. "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19". The New England Journal of Medicine 382 (19): 1787–1799. May 2020. doi:10.1056/NEJMoa2001282. PMID 32187464. 

External links